Leespharm gains Chinese rights to Zanidip
This article was originally published in Scrip
Executive Summary
The Hong Kong-based healthcare company Lee's Pharmaceutical Holdings (Leespharm) has acquired an exclusive licence for the marketing and sale of Recordati's antihypertensive Zanidip (lercanidipine) in China.